Polygenic risk score and statin relative risk reduction for primary prevention in a real-world population
View ORCID ProfileAkinyemi Oni-Orisan, View ORCID ProfileTanushree Haldar, View ORCID ProfileMari A. S. Cayabyab, Dilrini K. Ranatunga, Thomas J. Hoffmann, Carlos Iribarren, View ORCID ProfileRonald M. Krauss, Neil Risch
doi: https://doi.org/10.1101/2021.07.28.21254571
Akinyemi Oni-Orisan
aDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA
bInstitute for Human Genetics, University of California San Francisco, San Francisco, California, USA
cDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA
PharmD, PhDTanushree Haldar
aDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA
PhDMari A. S. Cayabyab
aDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA
PharmDDilrini K. Ranatunga
dKaiser Permanente Division of Research, Oakland, California, USA
BSThomas J. Hoffmann
bInstitute for Human Genetics, University of California San Francisco, San Francisco, California, USA
eDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
PhDCarlos Iribarren
dKaiser Permanente Division of Research, Oakland, California, USA
MD, MPH, PhDRonald M. Krauss
fDepartment of Pediatrics, University of California San Francisco, Oakland, California, USA
gDepartment of Medicine, University of California San Francisco, Oakland, Cali fornia, USA
MDNeil Risch
bInstitute for Human Genetics, University of California San Francisco, San Francisco, California, USA
dKaiser Permanente Division of Research, Oakland, California, USA
eDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
PhD
Posted July 29, 2021.
Polygenic risk score and statin relative risk reduction for primary prevention in a real-world population
Akinyemi Oni-Orisan, Tanushree Haldar, Mari A. S. Cayabyab, Dilrini K. Ranatunga, Thomas J. Hoffmann, Carlos Iribarren, Ronald M. Krauss, Neil Risch
medRxiv 2021.07.28.21254571; doi: https://doi.org/10.1101/2021.07.28.21254571
Polygenic risk score and statin relative risk reduction for primary prevention in a real-world population
Akinyemi Oni-Orisan, Tanushree Haldar, Mari A. S. Cayabyab, Dilrini K. Ranatunga, Thomas J. Hoffmann, Carlos Iribarren, Ronald M. Krauss, Neil Risch
medRxiv 2021.07.28.21254571; doi: https://doi.org/10.1101/2021.07.28.21254571
Subject Area
Subject Areas
- Addiction Medicine (322)
- Allergy and Immunology (626)
- Anesthesia (162)
- Cardiovascular Medicine (2359)
- Dermatology (206)
- Emergency Medicine (377)
- Epidemiology (11748)
- Forensic Medicine (10)
- Gastroenterology (700)
- Genetic and Genomic Medicine (3714)
- Geriatric Medicine (348)
- Health Economics (632)
- Health Informatics (2385)
- Health Policy (928)
- Hematology (340)
- HIV/AIDS (776)
- Medical Education (364)
- Medical Ethics (104)
- Nephrology (397)
- Neurology (3477)
- Nursing (197)
- Nutrition (522)
- Oncology (1813)
- Ophthalmology (534)
- Orthopedics (218)
- Otolaryngology (286)
- Pain Medicine (232)
- Palliative Medicine (66)
- Pathology (445)
- Pediatrics (1028)
- Primary Care Research (417)
- Public and Global Health (6122)
- Radiology and Imaging (1270)
- Respiratory Medicine (825)
- Rheumatology (379)
- Sports Medicine (320)
- Surgery (398)
- Toxicology (50)
- Transplantation (171)
- Urology (145)